Resources & Knowledge Center

Aridol is a bronchial challenge test that uses dry powder mannitol to identify airway hyperresponsiveness. It is indicated for the assessment of individuals who do not have clinically apparent asthma but may have underlying airway hyperresponsiveness. The test helps healthcare professionals diagnose asthma and assess the severity of airway inflammation.

The complete Aridol test typically takes 30-45 minutes, including patient preparation, baseline spirometry, dose administration, and post-test monitoring. The actual dosing sequence usually takes 15-20 minutes, with FEV₁ measurements taken 60 seconds after each dose. Additional time is required for post-test bronchodilator administration and monitoring until lung function returns to baseline.

To ensure accurate test results, certain medications should be withheld before testing:

• Short-acting beta-agonists (SABA): withhold for at least 4 hours
• Long-acting beta-agonists (LABA): withhold for at least 24 hours
• Inhaled corticosteroids: consider withholding for 24-48 hours if clinically appropriate
• Antihistamines: withhold for 72 hours

The most common side effects (incidence ≥5%) include:

• Headache (32%)
• Throat irritation (21%)
• Nausea (10%)
• Cough (9%)
• Chest discomfort (7%)

Most side effects are mild and resolve quickly. Emergency equipment and bronchodilators must be available during testing.

Yes, Aridol is approved for use in pediatric patients aged 6 years and older. The Pediatric Aridol Kit uses a modified dosing protocol optimized for children's respiratory systems, with a maximum cumulative dose of 400mg compared to 635mg for adults. Safety and efficacy have been established in clinical trials involving pediatric populations. Special consideration should be given to patient education and comfort measures when testing children.

Aridol offers several advantages over methacholine challenge testing: it uses a standardized dry powder formulation that is easier to store and administer, has a shorter testing time, and demonstrates comparable or superior sensitivity (98%) and specificity (95%). Aridol is also better tolerated by patients, with fewer side effects. The dry powder format eliminates the need for nebulizers and reduces preparation time. Both tests are FDA-approved for assessing airway hyperresponsiveness, and the choice between them depends on clinical requirements and facility capabilities.